Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 16/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594816 | 0.87 | CHRM3 (0.47) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL4408331 | 0.87 | CHRM3 (0.47) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL5962804 | 0.86 | HCRTR1 (0.42) | HCRTR1HCRTR2KMT2A | |
| SCHEMBL4408525 | 0.82 | ROCK2 (0.42) | HCRTR1HCRTR2CHRM3KMT2A | |
| SCHEMBL13594815 | 0.82 | ROCK2 (0.42) | HCRTR1HCRTR2CHRM3KMT2A | |
| SCHEMBL5962846 | 0.81 | EPHX2 (0.44) | CHRM3 | |
| SCHEMBL21352644 | 0.79 | HCRTR1 (0.41) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL21352645 | 0.79 | HCRTR1 (0.41) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL14071820 | 0.78 | HCRTR1 (0.44) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL20830995 | 0.77 | SMN1; SMN2 (0.36) | HCRTR1HCRTR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | HCRTR1 76/4885HCRTR2 23/4885CHRM3 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.